the control of ascariid infections in dogs, and as an aid in the treatment of ascariid infections in dogs and cats.

(b) Conditions of use—(1) Dosage/indications for use. (i) Three milligrams per pound of body weight daily for prevention of heartworm disease (Dirofilaria immitis) in dogs.

(ii) Three milligrams per pound of body weight daily as an aid in the control of ascariid infections (Toxocara canis) in dogs.

(iii) Twenty-five to 50 milligrams per pound of body weight as an aid in the treatment of ascariid infections in dogs (Toxocara canis) and cats (Toxocara canis and Toxascaris leonina).

(2) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(a)(1) Specifications. Each milliliter of syrup contains 60 milligrams of diethylcarbamazine citrate.

(2) Sponsor. See No. 000010 in §510.600(c) of this chapter.

§ 520.622b Diethylcarbamazine citrate syrup.

(a)(1) Specifications. Each milliliter of syrup contains 60 milligrams of diethylcarbamazine citrate.

(b) [Reserved]

(c)(1) Specifications. Each milliliter of syrup contains 60 milligrams of diethylcarbamazine citrate.

(ii) The drug is administered (a) for removal of ascariids at a dosage of 50 milligrams per pound of body weight divided into two equal doses and administered 8 to 12 hours apart (morning and night), orally or mixed with either dry or wet food, and (b) for prevention of heartworm disease at a dosage of 3 milligrams per pound of body weight daily, orally or in food, in heartworm endemic areas, from the beginning of mosquito activity, during the mosquito season, and for 2 months following the end thereof.

(iii) Dogs older than 8 months of age may be infected with Dirofilaria immitis. Use of the drug is contraindicated in dogs with active D. immitis infections.

(iv) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.622c Diethylcarbamazine citrate chewable tablets.

(a) Specifications. Each chewable tablet contains 30, 45, 60, 120, 150, or 180 milligrams of diethylcarbamazine citrate.

(b) Sponsors. See drug listing nos. in §510.600(c) of this chapter for identification of sponsors as follows: